Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Completed
Pfizer
Phase 2/Phase 3
2004-07-01
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is
non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria
due to P. falciparum.
Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria
Completed
McLaughlin-Rotman Center for Global Health, University of Toronto
Phase 1/Phase 2
2004-12-01
The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive
rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria
Completed
Mahidol University
Phase 1/Phase 2
2004-12-01
The purpose of this study is to examine the safety, tolerability, and efficacy of adjunctive
rosiglitazone in the treatment of uncomplicated P.falciparum malaria.
Chloroquine Alone or in Combination for Malaria in Children in Malawi
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
2007-02-01
Malaria is a sickness caused by a germ that can get into a person's body when a mosquito
bites them. It can cause fever, headache, body aches and weakness. It can even cause death,
especially in children. When malaria is treated with the appropriate medicine(s), it can be
cured completely. The purpose of this study is to find out if it is better to use chloroquine
alone or in combination with another drug to most effectively treat malaria. About 640
children with malaria, aged 6 months to 5 years of age, from the Blantyre Malaria Project
Research Clinic at the Ndirande Health Center in Malawi will be in the study. They will be
treated with either chloroquine alone or a combination of chloroquine plus another medication
(azithromycin or artesunate or atovaquone-proguanil) every time they get malaria for a year.
Blood samples will be collected and tested at least every 4 weeks. Participants will be
involved in the study for 1 year.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
